Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Novo Nordisk's 'There's Only One Ozempic' Campaign Reunites Stars - Featured image
GLP-1 Medications

Novo Nordisk's 'There's Only One Ozempic' Campaign Reunites Stars

Shotlee Editorial Team
Written by Shotlee Editorial TeamHealth Research & Writing
·January 20, 2026·5 min read

On this page

  • Novo Nordisk Launches Innovative Ozempic Campaign
  • Campaign Goals and Unique Approach
  • Ozempic's FDA-Approved Indications
  • Distinguishing Ozempic from Compounded Semaglutide
  • Actors' Perspectives on the Campaign
  • Important Safety Information for Ozempic
  • What is Ozempic?
  • What is the Most Important Information About Ozempic?
  • Before Using Ozempic
  • Possible Side Effects of Ozempic

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

Novo Nordisk introduces the 'There's Only One Ozempic' campaign, reuniting comedy duo Justin Long and John Hodgman to spotlight Ozempic's unique FDA-approved benefits for type 2 diabetes. The effort uses humor and education to distinguish genuine Ozempic (semaglutide) from unapproved compounded versions. It encourages vital conversations between patients and healthcare providers.

Share

On this page

  • Novo Nordisk Launches Innovative Ozempic Campaign
  • Campaign Goals and Unique Approach
  • Ozempic's FDA-Approved Indications
  • Distinguishing Ozempic from Compounded Semaglutide
  • Actors' Perspectives on the Campaign
  • Important Safety Information for Ozempic
  • What is Ozempic?
  • What is the Most Important Information About Ozempic?
  • Before Using Ozempic
  • Possible Side Effects of Ozempic

Novo Nordisk Launches Innovative Ozempic Campaign

Novo Nordisk announced a new consumer campaign for Ozempic (semaglutide) injection 0.5 mg, 1 mg, and 2 mg. Titled "There's Only One Ozempic," it reimagines traditional pharmaceutical advertising. The campaign features actors Justin Long and John Hodgman, known for their mid-2000s TV commercials.

Through levity, lively banter, and relatable everyday moments, the duo promotes informed discussions about GLP-1 treatment options. It targets adults with type 2 diabetes, highlighting Ozempic's FDA-approved uses amid a crowded market of GLP-1s and unapproved compounded "semaglutide."

Campaign Goals and Unique Approach

The campaign meets people where they are, using educational messages and humor to cut through the noise. It aims to foster meaningful conversations between consumers and healthcare professionals. By focusing on patient education, it spotlights what sets the iconic Ozempic brand apart.

"Not all GLP-1s are the same, and people with type 2 diabetes should talk with their doctors about whether Ozempic is right for them," said Ed Cinca, Senior Vice President, Marketing & Patient Solutions at Novo Nordisk Inc. "With our campaign, we're cutting through the noise with straightforward education about how Ozempic fits into care."

Ozempic's FDA-Approved Indications

Ozempic is the only FDA-approved GLP-1 that improves blood sugar along with diet and exercise and reduces the risk of major cardiovascular events and worsening kidney disease. This provides key information for choosing a type 2 diabetes treatment.

  • Improves blood sugar (glucose) in adults with type 2 diabetes, along with diet and exercise.
  • Reduces risk of major cardiovascular events (heart attack, stroke, or death) in adults with type 2 diabetes and known heart disease.
  • Reduces risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.

Ozempic has the most FDA-approved uses among GLP-1s for type 2 diabetes. It is not approved for use in children.

Distinguishing Ozempic from Compounded Semaglutide

In a landscape filled with unapproved compounded "semaglutide," clarity is crucial. Only Novo Nordisk manufactures FDA-approved semaglutide medicines like Ozempic. Products without the Ozempic label are not FDA-approved, lacking rigorous review for safety, effectiveness, and quality.

The campaign uses relatable storytelling and familiar voices to help information stand out. It encourages seeking credible details and discussing FDA-approved options with doctors.

Actors' Perspectives on the Campaign

"Humor has a way of opening the door to conversations people might otherwise avoid," said Justin Long. "This campaign uses that idea thoughtfully and meets people where they are consuming content while helping them feel comfortable enough to learn more about their health."

John Hodgman added, "It's important for people to learn more about their medication options and have that discussion with their doctors. What I appreciate about this campaign is the way it encourages meaningful conversations that can truly make a difference."

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

Justin Long and John Hodgman are paid spokespeople for Novo Nordisk and do not live with type 2 diabetes or take Ozempic.

Important Safety Information for Ozempic

Do not share your Ozempic pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.

What is the Most Important Information About Ozempic?

Ozempic may cause serious side effects, including possible thyroid tumors, including cancer. Tell your health care provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Ozempic and medicines that work like Ozempic caused thyroid tumors, including thyroid cancer. It is not known if Ozempic will cause thyroid tumors or medullary thyroid carcinoma (MTC) in people.

  • Do not use Ozempic if you or any of your family have ever had MTC or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Do not use Ozempic if you are allergic to semaglutide or any ingredients in Ozempic.

Before Using Ozempic

Tell your health care provider if you have:

  • Problems with your pancreas or history of diabetic retinopathy.
  • Severe stomach problems like gastroparesis.
  • Upcoming surgery or procedures with anesthesia.
  • Pregnancy plans or breastfeeding (stop Ozempic at least 2 months before planning pregnancy).

Inform your provider about all medicines, including insulin or sulfonylureas.

Possible Side Effects of Ozempic

Serious side effects may include:

  • Pancreatitis: Severe abdominal pain that may radiate to your back, with or without vomiting.
  • Changes in vision.
  • Hypoglycemia: Especially with sulfonylureas or insulin. Symptoms: dizziness, blurred vision, anxiety, sweating, hunger, shakiness, fast heartbeat.
  • Dehydration and kidney problems: From nausea, vomiting, diarrhea. Drink fluids to prevent.
  • Severe stomach problems.
  • Serious allergic reactions: Swelling, breathing issues, rash, rapid heartbeat.
  • Gallbladder problems: Upper abdominal pain, fever, jaundice.
  • Aspiration during surgery: Inform providers you take Ozempic.

Common side effects: nausea, vomiting, diarrhea, abdominal pain, constipation.

What is Ozempic?

Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:

  • Along with diet and exercise to improve blood sugar in adults with type 2 diabetes.
  • To reduce major cardiovascular event risk in adults with type 2 diabetes and heart disease.
  • To reduce worsening kidney disease risk in adults with type 2 diabetes and chronic kidney disease.

It is not known if Ozempic is safe and effective for children.

Source Information

Originally published by PR Newswire.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

What's the Deal with Peptides? The Hyped Market Under FDA Review
Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: Ozempic

All Ozempic articles →
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Pharmaceutical Industry News

Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics

Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.

8 min read

More in GLP-1 Medications

Matt Cooper Defends Ozempic Users: Early Adopter Story
GLP-1 Medications

Matt Cooper Defends Ozempic Users: Early Adopter Story

Radio host Matt Cooper reveals his journey as an early Ozempic adopter for type 2 diabetes. He defends users struggling with weight, sharing how the GLP-1 drug curbs appetite and led to gallbladder removal. Learn from his candid experiences on semaglutide benefits and challenges.

2 min read
Heather Gay Sticks with Ozempic GLP-1 for Wellness
GLP-1 Medications

Heather Gay Sticks with Ozempic GLP-1 for Wellness

Real Housewives star Heather Gay affirms she's not quitting GLP-1 medications like Ozempic. After losing 25 pounds since 2023, she emphasizes feeling energized through protein and fiber, not scale obsession. Her story highlights GLP-1s as part of a mindful wellness shift.

2 min read
Heather Gay: Sticking with GLP-1s After 25-lb Loss
GLP-1 Medications

Heather Gay: Sticking with GLP-1s After 25-lb Loss

Heather Gay, star of Real Housewives of Salt Lake City, shares her commitment to GLP-1 medications like Ozempic after shedding 25 pounds. She prioritizes how she feels over scale numbers, pairing the drug with Atkins for protein-rich nutrition. Now in her 50s, she feels healthier and more body-confident than ever.

3 min read
Share this article
  1. Home
  2. Blog
  3. Novo Nordisk's 'There's Only One Ozempic' Campaign Reunites Stars
Shotlee Editorial Team — Health Research & Writing
Written by

Shotlee Editorial Team

Health Research & Writing

Shotlee’s guides and articles are researched and written in-house by the Shotlee Editorial Team. We build every page from primary sources — FDA labels, official prescribing information, and peer-reviewed clinical trials — and cite them directly. Our content is educational and is not a substitute for advice from your own healthcare provider.

View all articles by Shotlee Editorial Team
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community